Chemistry: molecular biology and microbiology – Process of mutation – cell fusion – or genetic modification – Introduction of a polynucleotide molecule into or...
Reexamination Certificate
2006-07-11
2006-07-11
Chan, Christina (Department: 1644)
Chemistry: molecular biology and microbiology
Process of mutation, cell fusion, or genetic modification
Introduction of a polynucleotide molecule into or...
C435S348000, C435S320100, C536S023500
Reexamination Certificate
active
07074617
ABSTRACT:
The present invention relates to synthetic antigen-presenting matrices, their methods of making and their methods of use. One such matrix is cells that have been transfected to produce MHC antigen-presenting molecules with one or more accessory molecules. The matrices are used to activate naive CD4+T cells as well as shift the ongoing activation state into a preferred differentiated population of either Th1 or Th2 cells.
REFERENCES:
patent: 5242687 (1993-09-01), Tykocinski et al.
patent: 5314813 (1994-05-01), Peterson et al.
patent: 5395760 (1995-03-01), Smith et al.
patent: 5529921 (1996-06-01), Peterson et al.
patent: 5583031 (1996-12-01), Stern
patent: WO 96/12009 (1996-04-01), None
Janeway et al. Immunobiology Garland Press NY (1997) pp. 7:7, 7:8 and 7:25.
Galvin, et al., “Murine B7 Antigen Provides a Sufficient Costimulatory Signal for Antigen-Specific and MHC-Restricted T Cell Activation”.The Journal of Immunology 149: 3802-3808 (1992).
Baskar, et al, “Tumor Cells Expressing Major Histocompatibility Complex Class II and B7 Activation Molecules Stimulate Potent Tumor-Specific Immunity”,Journal of Immunotherapy14: 209-215 (1993).
Hemler, et al., Adhesive protein receptors in hematopoietic cells, 1998,Immunology Today,9(4):109-114.
Ratnofsky, et al., Expression and function of CD8 in a murine T cell hybridoma, 1987,J. Exp. Med.,166:1747-1757.
Sette, et al., Antigen analogs/MHC complexes as specific T cell receptor antagonists, 1994,Annu. Rev. Immunol.,12:413-431.
Tan, et al., Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1, 1993,J. Exp. Med.,177:165-173.
Brown, et al., CD27-CD27 ligand/CD70 interactio ns enhance alloantigen-induced proliferation cytolytic activity in CD8+ T lymphocytes, 1995,J. Immunol.,154:3686-3695.
Morris, et al., An essential role for HLA-DM in antigen presentation by class II major histocompatability molecules, 1994,Nature,368:551-554.
Jackson Michael R.
Karlsson Lars
Peterson Per A.
Webb Susan R.
Wingvist Ola
Chan Christina
Fitting Thomas
McCarthy Michael J.
The Scripps Research Institute
VanderVegt F. Pierre
LandOfFree
MHC class II antigen-presenting systems and methods for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with MHC class II antigen-presenting systems and methods for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and MHC class II antigen-presenting systems and methods for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3575776